About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Cancer in Patients With Gabapentin (GPRD) | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT01236053

Cancer in Patients With Gabapentin (GPRD)

High doses of gabapentin are associated with pancreatic acinar cell tumors in rats, but there has been no post marketing pancreatic carcinogenicity signal with gabapentin as reported by spontaneous re...

Lead sponsor: GlaxoSmithKline•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

GlaxoSmithKline

Actual number of patients may be less, as it is possible for a patient to be represented in more than one of the 22 arms (See "Participant Flow: Overall Study" Table) because of the risk set sampling.

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•The study cohort from which cases and controls are drawn is all subjects in the UK GPRD 1993-2008. Entry into the study cohort begins Jan 1, 1993 for all those who are registered in GPRD before that time, and at the time of registration if later than Jan 1, 1993. Follow-up ends Dec 31, 2008, or earlier if the subject leaves the GPRD for any reason including death.

Exclusion Criteria

•Subjects are excluded from the GPRD cohort if they have a cancer diagnosis or a history of cancer prior to the cohort entry date. Cases and controls will be required to have at least 2 years of follow-up in the study cohort before their index date (For cases, the index date is the date of first diagnosis of the respective cancer. The index date for controls is set as the date at which the follow-up time from cohort entry is the same as the case.) Cases must have no history of any other cancer diagnosis prior to the index date. Controls are required to be free of cancer diagnosis in the database up to the control's index date.

Related studies

RECRUITINGPhase 1

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

NCT02531880 · Epilepsy

The Clinical Utility of BioEP in Diagnostic Decision Making in Epilepsy

NCT06097195 · Epilepsy

RECRUITINGPhase 3

A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

NCT06315322 · Childhood Absence Epilepsy, Juvenile Absence Epilepsy

RECRUITINGPhase 1/2

A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy

NCT06388707 · Drug Resistant Epilepsy, Epilepsy, and more

RECRUITINGPhase 3

Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures

NCT07505004 · Focal Epilepsy

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 6, 2017Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment2,323,608

Start dateJun 2010

Last updatedJul 6, 2017

Condition

Pain, Neuropathic Epilepsy Renal Pelvis Cancer Pancreatic Cancer Breast Cancer+11 more

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 6, 2017Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions